Mona Bafadhel
University of Oxford
H-index: 40
Europe-United Kingdom
Top articles of Mona Bafadhel
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled …
The Lancet Respiratory Medicine
2024/1/1
Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 …
2024/5
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19
ERJ Open Research
2024/1/1
Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial
2024/5
Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the …
2024/5
In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to …
2024/5
Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study
2024/5
Efficacy of Mepolizumab in Patients With COPD and an Eosinophilic Phenotype With Chronic Bronchitis-A Post Hoc Analysis of the METREX & METREO Phase 3 Studies
2024/5
Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels< 20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary …
2024/5
Efficacy of Mepolizumab in Patients With Chronic Obstructive Pulmonary Disease With or Without Chronic Bronchitis: Post Hoc Analysis of the METREX and METREO Phase 3 Trials
2024/5
Development and validation of a new algorithm for improved cardiovascular risk prediction
Nature Medicine
2024/4/18
Mona Bafadhel
H-Index: 27
Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
CHEST
2023/10/1
Functional MRI assessment of the lungs in fetuses that deliver very Preterm: An MRI pilot study
European Journal of Obstetrics & Gynecology and Reproductive Biology
2024/2/1
In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation
2024/5
Efficacité et sécurité du dupilumab chez des patients atteints de BPCO avec une inflammation de type 2 (élévation des éosinophiles)
Revue des Maladies Respiratoires Actualités
2024/1/1
Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial
JAMA dermatology
2023/3/1
How have we measured trial outcomes of asthma attack treatment? A systematic review
2024/1/1
Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
The Lancet Regional Health–Europe
2023/6/1
Efficacy and Safety of Dupilumab in COPD with Type 2 Inflammation Guided by Blood Eosinophils: The BOREAS Study
The New England Journal of Medicine
2023/5/21
Mona Bafadhel
H-Index: 27
Xin Lu
H-Index: 1
A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD
International journal of chronic obstructive pulmonary disease
2023/12/31
Cono Ariti
H-Index: 29
Mona Bafadhel
H-Index: 27
Jiandong Zhou
H-Index: 6
Xiao Xu
H-Index: 11
David Price
H-Index: 11
